US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.34 against a street estimate of -0.23 — a miss of 47.8%.
Analysts rate Harrow Health Inc a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $65.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.31% |
| Opaleye Management Inc | 6.40% |
| Private Capital Management, LLC | 4.26% |
| Vanguard Capital Management, LLC | 3.78% |
| Deep Track Capital, LP | 2.58% |
| State Street Corp | 2.51% |
| Geode Capital Management, LLC | 2.42% |
| BAMCO Inc | 2.16% |
| Document | Date |
|---|---|
| Material agreement · Q4 2026 HEADLINE NUMBERS • Harrow completed the acquisition of TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris on October 1, 2026. • TYRVAY | 2026-10-05 |
| Board / officer change · Q3 2026 HARROW, INC. - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Harrow, Inc. (ticker: HROW) is a Delaware-incorporated company headquartered in Nash | 2026-09-04 |
| Quarterly report · Q2 2026 HARROW, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues (6M 2026): $114.9 million (vs. $111.6 million in 6M 2025; +3.0% YoY) • Net los | 2026-08-10 |
| Results announced · Q3 2026 HARROW HEALTH INVESTOR SUMMARY Q2 2026 Letter to Stockholders --- HEADLINE NUMBERS • Q2 2026 revenue: $70.7 million (60% sequential increase from Q | 2026-08-10 |
| Material agreement · Q3 2026 HARROW, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Acquisition price: $30 million upfront cash payment at closing • Additional contingent payments: | 2026-08-06 |
| Shareholder vote results · Q2 2026 HARROW, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 18, 2026 • Total shares entitled to vote: 37,273,420 • Shares present or | 2026-06-22 |
| Quarterly report · Q1 2026 HARROW, INC. – FORM 10-Q SUMMARY Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Total Revenues: $44.2 million (Q1 2026) vs. $47.8 million (Q1 | 2026-05-11 |
| Proxy statement · Q4 2025 HARROW, INC. PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of four directors (Mark L. Baum, Adrienne L. Graves, Lau | 2026-04-24 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Harrow Health Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.